---
title: "Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)"
nct_id: NCT03880513
overall_status: COMPLETED
sponsor: Wuerzburg University Hospital
study_type: OBSERVATIONAL
primary_condition: "Endogenous Cushing's Syndrome"
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03880513.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03880513"
ct_last_update_post_date: 2023-04-28
last_seen_at: "2026-05-12T06:54:48.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)

**NCT ID:** [NCT03880513](https://clinicaltrials.gov/study/NCT03880513)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 108
- **Lead Sponsor:** Wuerzburg University Hospital
- **Conditions:** Endogenous Cushing's Syndrome
- **Start Date:** 2014-10
- **Completion Date:** 2022-10
- **CT.gov Last Update:** 2023-04-28

## Brief Summary

Within this trial, the cardiovascular and mental status as well as the metabolic profiles of patients with endogenous cortisol excess are evaluated.

## Detailed Description

Endogenous Cushing's syndrome (CS) is associated with increased cardiovascular (CV) morbidity and reduced general health status. It has been shown that these impairments may be reversible after cure of hypercortisolism. However, previous studies were restricted to selected CV aspects.

The primary aim of the CV-CORT-EX study is to comprehensively assess left ventricular function and morphology of patients with endogenous CS. Secondly, we examine long-term changes of CV function, endothelial function, psychosocial status, bio-impedance, and quality of life.

Within the longitudinal study, patients will be investigated at initial diagnosis and at least 6 months after cure of CS. Within the cross-sectional study, we aim to comprehensively phenotype patients with endogenous CS and unknown CV disease. Results will finally be compared with healthy controls.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Written informed consent
* Age ≥18 years
* Cross-sectional study:History of clinically and biochemically proven endogenous Cushing's syndrome (overt or subclinical)
* Longitudinal study: Patients with clinically and biochemically proven endogenous Cushing's syndrome (initial diagnosis or recurrent disease)

Exclusion Criteria:

* Glucocorticoid pharmacotherapy for \>12 months within the previous 3 years
* Structural heart disease, chronic heart failure (\>NYHAII), systemic or single organ disease potentially affecting cardiac function
* Arterial hypertension (uncontrolled with \>3 antihypertensive drugs)
* Pregnancy
* Drug abuse
* Cardiac Magnetic Resonance Imaging (cMRI) substudy: patients with renal failure are excluded from the cMRI study (MDRD \<60)
```

## Arms

- **Longitudinal study** — Patients during overt and after cure of endogenous Cushing's syndrome.
- **Cross-sectional study** — Patients with proven endogenous Cushing's syndrome (overt or subclinical).

## Interventions

- **Cardiovascular status and quality of life** (DIAGNOSTIC_TEST) — Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment

## Primary Outcomes

- **Cardiovascular status - pathological cardiac MRI** _(time frame: 7 years)_ — Number of patients with pathological results (ejection fraction (\<55%), pericardial effusion, thrombus, adipose tissue, perfusion defects, late enhancement, valvular or wall motion abnormalities).

## Secondary Outcomes

- **Cardiovascular status - pathological cardiac echocardiography** _(time frame: 7 years)_

## Locations (1)

- University Hospital Wuerzburg, Würzburg, Bavaria, Germany

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital wuerzburg|würzburg|bavaria|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03880513.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03880513*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*